Navigation Links
Medimetriks Pharmaceuticals Launches Two New Prescription Brands
Date:4/27/2009

FAIRFIELD, N.J., April 27 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company launched Centany(R) (mupirocin ointment, 2%) and Uramaxin(TM) (20% Urea) Foam to its core Dermatology and Podiatry physician audiences. Centany(R) received a New Drug Approval in December 2002 and is patented through 2018. Centany(R) represents a significant step in Medimetriks' plan to commercialize patent-protected therapies that offer important patient benefits. Uramaxin(TM) Foam represents a valuable addition to the Company's Uramaxin(TM) Family of urea-based brands. Both of these brands come to Medimetriks as the result of a licensing agreement with Perrigo Company (Nasdaq: PRGO) for U.S. marketing rights.

Centany(R), previously marketed by Johnson & Johnson's Ortho Dermatologics professional division, is indicated for the topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150 million. In addition to a 94% clinical efficacy rate(1) and a 98% eradication of staph and strep*, Centany(R) provides an enhanced safety profile over other mupirocin-based therapies. Centany(R) is the only mupirocin ointment indicated for impetigo free of polyethylene glycol(2), an ingredient found in other mupirocin ointments that carry warnings for patients with impaired kidney function. Centany(R)'s unique vehicle also offers the cosmetically elegant texture of a cream with the occlusive properties of an ointment, providing patients with a therapeutic alternative that may enhance patient compliance. Based on the unique properties of its vehicle, Centany(R) is BX-rated by the FDA and designated as non-substitutable.

Uramaxin(TM) Foam is 20% urea in a vehicle containing ammonium lactate. These components make up the vast majority of prescriptions written by Dermatologists and Podiatrists for dry skin conditions. Uramaxin(TM) Foam is an effective, low-potency keratolytic that complements Uramaxin(TM) (45% Urea) Nail Gel and Uramaxin(TM) (45% Urea) Cream, high-potency keratolytics previously launched by the Company. The foam delivery system is a format gaining wide acceptance by both physicians and patients, and Uramaxin(TM) Foam is provided in a large size to add value to patients. Uramaxin(TM) Foam will compete in a skin softening market that approaches one million prescriptions annually.

Medimetriks CEO and Chairman, Bradley Glassman, commented, "We are pleased to add these prescription brands to our portfolio of therapies that provide value to both patients and physicians. Since the introduction of Medimetriks on May 1st of 2008, the Company has now launched six prescription therapies. These brands will be promoted by an expanding field force that we expect to reach more than 30 professional representatives within the next nine months."

*One week after therapy.

(1)Centany(R) Prescribing Information, Fairfield, NJ: Medimetriks Pharmaceuticals, October 2008.

(2)Data on file, Medimetriks Pharmaceuticals.

Centany(R) is contraindicated in individuals with a history of sensitivity reactions to any of its components. The following local adverse reactions have been reported in connection with the use of Centany(R): application site reactions and pruritus, each in 1% of patients; contact dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.

Uramaxin(TM) Foam is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappears after discontinuing the medication.

Please see full prescribing information at www.medimetriks.com

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.


'/>"/>
SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
2. Medimetriks Pharmaceuticals Launches Companys First Prescription Brands
3. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
4. PUR Water Filtration Systems Can Reduce Trace Levels of Pharmaceuticals Found in Some U.S. Tap Water
5. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
6. Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
9. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
10. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
11. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... In the Health Care IT campaign, Robert Herjavec discusses health IT security ... will be attacked, but when.” However, he and many others involved highlight a promising ... in auditing and monitoring have taken security in health care a very long way. ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have ... Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, ... Pro X. , With ProGlass Prism users are given the tools and effects ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle ... hosted their Military Wedding Giveaway, with the winning couple announced on Feb. 14, ... services generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG ... für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des ... ultraviolette Strahlung im Bereich zwischen 200 und 280 nm und ... von Bakterien, indem es ihre DNA zerstört. Das Produkt ... ...
(Date:2/23/2017)... -- Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden ... Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... York , February 23, 2017 ... arising from increasing caseload for varicose veins in their ... the globe are prompting the adoption of endovenous laser ... on global endovenous laser therapy market, published ... aftereffects of lifestyle choices and consequences of obesity have ...
Breaking Medicine Technology: